Copyright
©The Author(s) 2022.
World J Exp Med. May 20, 2022; 12(3): 36-43
Published online May 20, 2022. doi: 10.5493/wjem.v12.i3.36
Published online May 20, 2022. doi: 10.5493/wjem.v12.i3.36
Ref. | Publication year and study period | Histology | Number of patients | Age (yr) | Setting | Treatment | Tumor size | Dose | Prior RT | Follow-up duration | PFS / tumor control |
Murphy et al[42] | 2019 (1990-2016) | PA | 141 | Median age 14 yr (range: 2-84 yr) | As part of initial management or salvage therapy | GKSRS | Median 3.45 cc | Median margin dose 16 Gy | 21 patients | Median 67.3 mo | PFS 74.0% at 5 yr; PFS 69.7% at 10 yr |
Trifiletti et al[43] | 2017 (1990-2015) | PA | 28 | Median age 17.4 yr (range: 2-70.3 yr) | As part of initial management or salvage therapy | GK-based SRS or SRT | Median 1.84 cc | Median margin dose 16 Gy for single fraction SRS, and 15 Gy delivered in 3 fractions for SRT | 4 patients | Median 5.4 yr | PFS 96% at 6 yr; Tumor control 93% |
Simonova et al[44] | 2016 (1992-2002) | PA | 25 | Median age 13 yr (range: 3-17 yr) | As part of initial management or salvage therapy | GK-based SRS or SRT | Median 2.7 cc | Median margin dose 16 Gy for patients receiving single fraction, median dose 25 Gy delivered in 5 fractions for SRT | 2 patients | Median 15 yr | PFS 80% at 10 yr |
Lizarraga et al[45] | 2012 (1995-2010) | PA | 12 | Median age 21 yr (range: 5-41 yr) | Salvage therapy | LINAC-based SRS or SRT | Median 6.5 cc for SRT; Median 1.69 cc for SRS | Median dose 18.75 Gy for SRS and median dose 50.4 Gy delivered in 28 fractions for SRT | 0 patients | Median 37.5 mo | PFS 73.3% at long term |
Hallemeier et al[46] | 2012 (1992-2005) | PA | 18 | Median age 23 yr (range: 4-56 yr) | As part of initial management or salvage therapy | GKSRS | Median 9.1 cc | Median margin dose 15 Gy | 10 patients | Median 8 yr | PFS 41% at 5 yr; Tumor control 75% |
Kano et al[47] | 2009 (1987-2006) | PA | 50 | Median age 10.5 yr (range: 4.2-17.9 yr) | As part of initial management or salvage therapy | GKSRS | Median 2.1 cc | Median margin dose 14.5 Gy | 5 patients | Median 55.5 mo | PFS 70.8% at 5 yr |
Kano et al[48] | 2009 (1994-2006) | PA | 14 | Median age 32 yr (range: 19-52 yr) | As part of initial management or salvage therapy | GKSRS | Median 4.7 cc | Median margin dose 13.3 Gy | 6 patients | Median 36.3 mo | PFS 31.5% at 5 yr |
Hadjipanayis et al[49] | 2002(1987-2000) | PA | 37 | Median age 14 yr (range: 3-52 yr) | As part of initial management or salvage therapy | GKSRS | Median 3 cc | Median margin dose 15 Gy | 9 patients | Median 28 mo after GKSRS | Tumor control 68% |
Boëthius et al[50] | 2002 (1978-1997) | PA | 19 | Mean age 10.6 yr (range: 2-60 yr) | Adjuvant therapy | GKSRS | Median 2.2 cc | Median margin dose 10 Gy | 2 patients | Median radiological follow-up 4.7 yr | Tumor control 94.7% |
Somaza et al[51] | 1996 (1990-1993) | PA | 9 | Mean age 8.6 yr (range: 4-17 yr) | Adjuvant or salvage therapy | GKSRS | Mean tumor diameter 16 mm | Median margin dose 15 Gy | 2 patients | Median 19 mo | Tumor control 100% |
- Citation: Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, Gumustepe E, Ozcan F, Colak O, Gursoy AT, Dursun CU, Tugcu AO, Dogru GD, Arslan R, Elcim Y, Gundem E, Dirican B, Beyzadeoglu M. Concise review of radiosurgery for contemporary management of pilocytic astrocytomas in children and adults. World J Exp Med 2022; 12(3): 36-43
- URL: https://www.wjgnet.com/2220-315x/full/v12/i3/36.htm
- DOI: https://dx.doi.org/10.5493/wjem.v12.i3.36